TickerFacts.

Tenaya Therapeutics, Inc. (TNYA): Cash & Equivalents

Annual figures by period end, from SEC filings.

$100.55M
As of 2025-12-31
$78.08M
As of 2026-06-30
+1.8%
3-year compound annual growth
-4.8%
5-year compound annual growth
$128.53M2020-12-31: $128.53M2021-12-31: $38.13M2022-12-31: $95.27M2023-12-31: $45.68M2024-12-31: $4.32M2025-12-31: $100.55M$100.55M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$100.55Mn/m2026-03-11, Balance as of period end
2024-12-31$4.32M-90.5%2026-03-11, Balance as of period end
2023-12-31$45.68M-52.1%2025-03-10, Balance as of period end
2022-12-31$95.27M+149.9%2024-03-18, Balance as of period end
2021-12-31$38.13M-70.3%2023-03-08, Balance as of period end
2020-12-31$128.53Mn/a2022-03-23, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Tenaya Therapeutics, Inc. (TNYA)2025-12-31$100.55Mn/m
Inhibrx Biosciences, Inc. (INBX)2025-12-31$124.22M-18.6%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$20.99M-42.4%
ImageneBio, Inc. (IMA)2025-12-31$94.53M+680.1%
Precision Biosciences Inc (DTIL)2025-12-31$110.82M+29.0%
Compugen Ltd (CGEN)2025-12-31$90.60M+397.0%
Palisade Bio, Inc. (PALI)2025-12-31$133.38Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$26.70M-33.6%
Cabaletta Bio, Inc. (CABA)2025-12-31$82.98M-49.4%

Compare TNYA, INBX, BDTX, IMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗